眾生藥業(002317.SZ):子公司利福平膠囊通過一致性評價
格隆匯11月9日丨眾生藥業(002317.SZ)公佈,近日,公司全資子公司廣東華南藥業集團有限公司(簡稱“華南藥業”)收到國家藥監局批准簽發的《藥品補充申請批准通知書》,通知書編號:2022B04769。華南藥業的利福平膠囊通過了仿製藥質量和療效一致性評價。
利福平是一種所屬利福黴素家族的一種廣譜抗生素藥物,對結核桿菌有較強抗菌作用,對革蘭氏陽性或陰性細菌、病毒等也有療效。與其他抗結核藥(如鏈黴素、異煙肼、吡嗪酰胺及乙胺丁醇)聯合用於治療結核病。
根據米內網數據庫顯示,利福平膠囊2019至2021年在中國城市公立醫院及中國城市實體藥店的銷售總額合計為人民幣1.09億元、9690萬元、1.21億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.